Journal article
Five-year antibody persistence and safety after a single dose of combined haemophilus influenzae Type B neisseria meningitidis Serogroup C-tetanus toxoid conjugate vaccine in haemophilus influenzae Type B-primed toddlers
R Booy, T Nolan, G Reynolds, P Richmond, M Nissen, H Marshall, T Stoney, M Van Der Wielen, D Kolhe, JM Miller
Pediatric Infectious Disease Journal | Published : 2015
Abstract
Background: Antibody persistence is evaluated in healthy Australian children 4 and 5 years postvaccination with a single dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) compared with separately administered Hib-TT and MenC-CRM197 vaccines (Hib + MCC). Methods: This is another follow-up of a phase III, open, randomized, controlled study (NCT00326118), in which 433 Hib-primed but MenC naïve toddlers aged 12-18 months were randomized 3:1 to receive Hib-MenC-TT or Hib + MCC vaccines. Protection against (1) MenC was measured by serum bactericidal antibody assay using rabbit complement (rSBA) and (2) Hib was measured ..
View full abstractGrants
Awarded by NHMRC Career Development Fellowship
Funding Acknowledgements
Supported by GlaxoSmithKline Biologicals SA and was involved in all stages of the study conduct and analysis and also funded all costs associated with the development and the publishing of the present manuscript. H. M. acknowledges support of a NHMRC Career Development Fellowship (1016272). The institutions of R. B., T. N., G. R., P. R. and H. M. received grants from GSK group of companies during the submitted work. The institution of R. B. received grants and, on occasions, honoraria from Australian-based companies. The institution of T. N. received grants from Sanofi-Pasteur during the submitted work. T. N. also declares personal fees, travel and accommodation support from GSK outside the submitted work. P. R. declares grants from GSK, Novartis and Pfizer and nonfinancial travel support from Sanofi and Pfizer, outside the submitted work. M. N. declares grants from GSK and Sanofi Pasteur and membership in advisory boards for Novartis and Pfizer, outside the submitted work. The institution of H. M. also declares grants, honorarium and board membership for GSK outside the submitted work and grants from Novartis, CSL and Pfizer. T. S. declares personal fees and travel support from GSK, Novartis Vaccines and Diagnosis, Sanofi Pasteur and grants from CSL outside the submitted work. M. V. W., D. K. and J. M. M. are employees of GSK group of companies. M. V. W. and J. M. M. declare restricted shares in GSK group of companies. J. M. M. is coinventor of a patent which, if granted, will be owned by GSK. The other authors have no conflicts of interest to disclose.